Qcil presentation health care conference

679 views

Published on

Published in: Business, Health & Medicine
0 Comments
2 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
679
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
6
Comments
0
Likes
2
Embeds 0
No embeds

No notes for slide

Qcil presentation health care conference

  1. 1. ACCESS TO QUALITY AND  AFFORDABLE ARVS IN EAST AFRICABYEMMANUEL KATONGOLEDIRECTOR /CHIEF EXECUTIVE OFFICER (CEO)QUALITY CHEMICAL INDUSTRIES LTDP.O.BOX 34871KAMPALA- UGANDA “Affordable access to Quality medicines”
  2. 2. BACKGROUND About 35 pharmaceutical manufacturers in East Africa but only 2 have WHO cGMP. Over 80% medicines for the region are imported. Current access to ARVs in the region is about 40% of those in need.o Resistance to the 1st line ARVs is beginning to be recorded hence the need for new ARVs.
  3. 3.    UGANDA INTERVENTION: QCIL Burden of disease is predominantly African i.e. 63% of Global HIV/AIDS is home to Africa. To mitigate the adverse effects of the World Trade Organisation on Trade Related Aspects of Intellectural Property Rights (TRIPs)on access to affordable, newer and safer medicines for the poor. To take early and full advantage of the flexibilities and exemptions provided under the TRIPs agreement. d The Pharmaceutical plant is in line with Uganda Government’s Industrialisation policy with its numerous attendant benefits
  4. 4. PLANT CAPACITY 6,000,000 tablets per day in 3 shifts which is 1.6 billion tabletsa yearCurrent capacity utilization is 60% covering Uganda market.Signed 5 year MOU with Kenya.Advanced negotiations with RwandaMid this year we plan to a USD 50 million 2nd phase plantwhich will triple our capacity to 18 million tablets per day.
  5. 5. PRODUCTSCurrent products Anti-malarial products - Lumartem Tablets (Artemether and Lumefantrine) Anti-retroviral products - Duovir-N (Lamivudine, Nevirapine and Zidovudine fixed dose combination - Duovir ( Lamivudine and Zidovudine) - Effavir (Effavirenz)New products- Tenofovir- Emitricitabine- Lumartem Forte
  6. 6. ACHIEVEMENTS TODATEINTERNATIONAL CERTIFICATIONS: World Health Organization  (WHO) Good Manufacturing  Practices for plant and product attained. International Committee of Red Cross (ICRC) certification Drugs for Neglected Diseases Initiative (DNDI) certification National Drug Authority  GMP and products marketing  authorisation got from Kenya Pharmacy and Poisons Board GMP  certification. Tanzania Food and Drugs Administration  (TFDA)   inspected the  plant and await  GMP certification
  7. 7. ACHIEVEMENTS TODATE CONT’DCompleted registration in Rwanda and Burundi.Participating under the Global fund –AMFm project as a mastersupplier of ACTs.Has helped curb shortages of ARVs and ACTs in the public sector.Over 200 jobs provided directly to Pharmacists, Biochemists,Chemical engineers, microbiologists, Civil, electrical, mechanicalengineers etc.90% employees are Locals. 1,000 indirect employments forsupport industries (51 suppliers)
  8. 8. CHALLENGES Dumping from overseas in a bid t buy markets: India and China subsidize finished pharmaceuticals exports by up to 30% thus making them artificially cheap. This is killing local capacity development.• Fragmented market Lack of skilled manpower Harmonization of medicines regulations in the region. Investment in research and development
  9. 9. CONCLUSIONPublic Private Partnerships in anintegrated East Africa common marketapproach will be key to sustainable accessof affordable medicines in the region.
  10. 10. THANK YOU

×